黄斑区格栅样光凝联合雷珠单抗对糖尿病性黄斑水肿患者血清VEGF和IL-6水平影响

Abstract
Figure/Table
References
Related Citation (2)

Download: PDF (2087 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the effect of grid like photocoagulation in the macular region combined with Leizumab on serum Vascular endothelial growth factor (VEGF) and interleukin-6(IL-6) levels in patients with diabetes macular edema (DME). Methods Patients with DME 98 cases admitted to Chengdu 363 Hospital from January 2021 to January 2023 were selected and randomly divided into two groups using a single blind randomized control method based on a random number table, with 49 patients in each group. The patients in the control group were treated with macular grid photocoagulation, and the patients in the observation group were treated with macular grid photocoagulation combined with leizumab. There were compared two groups preoperative, postoperative 1 month and 6 TMV, CME and corrected best visual, before operation and 6 months after operation serum VEGF and IL-6, and 6 months after operation curative effect. Results Compared preoperative, TMV and CME of to groups were decreased at postoperative 1 month and 6 months and in the observation group were lower than those in the Compared preoperative, two groups best corrected visual acuity were increased of postoperative 1 month and 6 months; at postoperative 1 month and 6 months, observation group best corrected visual acuity higher control group. Compared preoperative, two groups serum VEGF and IL-6 levels were decreased of postoperative 6 months; at postoperative 6 months, observation group serum VEGF and IL-6 levels lower control group. At postoperative 6 months, observation group total effective rate was higher than control group. Conclusion Macular grid photocoagulation combined with rezumab is effective in treating DME, it can effectively improve vision, and relieve macular edema, and reduce serum IL-6 and VEGF levels.

Key words： macular grid photocoagulation leizumab diabetic macular edema best corrected vision vascular endothelial growth factor interleukin-6

Received: 07 March 2024

PACS:

R77

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	TANG Huichao
	LI Man
	WANG Dongmei
	ZHOU Yu
	PANG Jiuyan
	YANG Wei
	LIU Xingyu

Cite this article:

TANG Huichao,LI Man,WANG Dongmei等. Effects of grid like photocoagulation in macular region combined with ranzumab on serum VEGF and IL-6 levels in patients with diabetes macular edema[J]. HuNan ShiFan DaXue XueBao(YiXueBan), 2024, 21(3): 51-54.

URL:

http://yxb.hunnu.edu.cn/EN/ OR http://yxb.hunnu.edu.cn/EN/Y2024/V21/I3/51

[1] JHAVERI CD, GLASSMAN AR, FERRIS FL, et al.Aflibercept Monotherapy or Bevacizumab First for Diabetic Macular Edema[J]. N Engl J Med, 2022, 387(8): 692-703.
[2] MADJEDI K, PEREIRA A, BALLIOS BG, et al.Switching between anti-VEGF agents in the management of refractory diabetic macular edema: A systematic review[J]. Surv Ophthalmol, 2022, 67(5): 1364-1372.
[3] KODJIKIAN L, BANDELLO F, SMET M, et al.Fluocinolone acetonide implant in diabetic macular edema: International experts' panel consensus guidelines and treatment algorithm[J]. Eur J Ophthalmol, 2022, 32(4): 1890-1899.
[4] 苏锐锋, 李晓红, 李新秀, 等. 内界膜剥除治疗顽固性糖尿病性黄斑水肿的疗效以及对视功能的影响[J]. 实用医学杂志, 2021, 37(14): 1811-1814.
[5] 宋泽娟, 徐静, 李婵. 羟苯磺酸钙联合康柏西普治疗糖尿病性黄斑水肿的疗效和安全性[J]. 眼科新进展, 2021, 41(1): 75-78.
[6] 张昊瑞, 桂潇, 赵娜, 等. 糖尿病性黄斑水肿的药物治疗研究进展[J]. 中国眼耳鼻喉科杂志, 2021, 21(3): 226-229.
[7] 朱澜澜, 高自清, 戴青. 房水中IL-6、TNF-α和VEGF的变化与糖尿病性黄斑水肿的相关性研究[J]. 临床眼科杂志, 2022, 30(4): 316-320.
[8] QASSIMI NA, KOZAK I, KARAM MA, et al.Management of Diabetic Macular Edema: Guidelines from the Emirates Society of Ophthalmology[J]. Ophthalmol Ther, 2022, 11(5): 1937-1950.
[9] MIRSHAHI R, FALAVARJANI KG, MOLAEI S, et al.Macular microvascular changes after intravitreal bevacizumab injection in diabetic macular edema[J]. Can J Ophthalmol, 2021, 56(1): 57-65.
[10] SOROUR OA, LEVINE ES, BAUMAL CR, et al.Persistent diabetic macular edema: Definition, incidence, biomarkers, and treatment methods[J]. Surv Ophthalmol, 2023, 68(2): 147-174.
[11] OZCALISKAN S, PEHLIVANOGLU S, HUSEYINHAN Z, et al.Macular and peripapillary microvasculature after dexamethasone injection in diabetic macular edema[J]. Eur J Ophthalmol, 2022, 32(5): 2752-2759.
[12] 王红燕, 朱卫华, 刘小峰. 补阳还五汤加减联合激光治疗糖尿病性黄斑水肿临床研究[J]. 陕西中医, 2021, 42(7): 896-899.
[13] 白淑玮, 毕春潮, 邵娟, 等. 玻璃体切割手术联合全视网膜光凝术治疗糖尿病视网膜病变临床疗效观察[J]. 陕西医学杂志, 2020, 49(12): 1569-1572.
[14] HUI VWK, SZETO SKH, TANG FY, et al.Optical Coherence Tomography Classification Systems for Diabetic Macular Edema and Their Associations With Visual Outcome and Treatment Responses - An Updated Review[J]. Asia Pac J Ophthalmol, 2022, 11(3): 247-257.
[15] 邓爱萍, 田润, 熊成, 等. 地塞米松玻璃体内植入剂早期联合康柏西普在抗血管内皮生长因子治疗反应不佳糖尿病性黄斑水肿中的应用[J]. 眼科新进展, 2023, 43(9): 722-726.
[16] 张少华, 张超, 张鹏. 阿柏西普治疗不同类型糖尿病黄斑水肿临床效果及影响因素[J]. 陕西医学杂志, 2022, 51(7): 874-877+881.
[17] 夏侯梨. 雷珠单抗玻璃体内注射联合超声乳化治疗白内障合并糖尿病性黄斑水肿的疗效[J]. 检验医学与临床, 2023, 20(5): 677-679.
[18] 赵鑫, 胥朵, 李少海, 等. 桃红四物汤合六味地黄汤联合雷珠单抗玻璃体内注射治疗糖尿病性黄斑水肿疗效观蔡[J]. 四川中医, 2022, 40(2): 130-133.
[19] 吴兵, 孙峰, 杨学龙. 阿柏西普和雷珠单抗治疗糖尿病性黄斑水肿的疗效[J]. 国际眼科杂志, 2023, 23(8): 1395-1398.
[20] 祁媛媛, 崔林, 张莉, 等. 反复玻璃体腔注射雷珠单抗与阿柏西普对黄斑水肿患者角膜神经的影响[J]. 国际眼科杂志, 2023, 23(5): 848-851.
[21] 田涛, 姚晓喜, 彭婧利, 等. 不同抗VEGF药物治疗糖尿病性黄斑水肿的疗效及其与OCT分型的关系[J]. 国际眼科杂志, 2023, 23(6): 991-995.
[22] 王秀先, 张培成, 谢静, 等. 阿柏西普与雷珠单抗治疗糖尿病性黄斑水肿的疗效比较[J]. 国际眼科杂志, 2021, 21(12): 2183-2186.
[23] 朱澜澜, 高自清, 戴青. 房水中IL-6、TNF-α和VEGF的变化与糖尿病性黄斑水肿的相关性研究[J]. 临床眼科杂志, 2022, 30(4): 316-320.
[24] 田涛, 姚睿, 彭婧利, 等. miR-106调控CC趋化因子配体2对增生型糖尿病视网膜病变中人视网膜微血管内皮细胞增殖, 血管生成和炎症反应的影响[J]. 眼科新进展, 2021, 41(9): 831-837.
[25] 姬翔, 李杰, 张翔, 等. 糖尿病患者糖化血红蛋白、总胆固醇及血管内皮生长因子水平与白内障术后黄斑水肿的相关性研究[J]. 中华眼外伤职业眼病杂志, 2023, 45(7): 492-497.